May 19, 2009 — Oral iron-chelation products have been heavily promoted for use in patients with myelodysplastic syndrome (MDS) and, recently, in patients with primary myelofibrosis (PMF), but this use ...

Background: Growing body of evidence suggests that Parkinson's disease (PD) is associated with oxidative damage via iron accumulation in the substantia nigra (SN). Low ceruloplasmin (CP)-ferroxidase ...

Iron Chelation Therapy Fails to Prevent Reperfusion Injury After STEMI Adjunctive chelation therapy with deferoxamine after the onset of ischemia in patients treated by primary percutaneous coronary ...

Brain iron chelation with deferiprone was associated with worse parkinsonism symptoms and adverse events in early Parkinson's disease, the FAIRPARK-II trial showed. From baseline to week 36, mean ...

Oncotarget published "Eltrombopag and its iron chelating properties in pediatric acute myeloid leukemia" which reported that the standard treatment for pediatric AML currently consists in a ...

Starting iron chelation therapy early may prevent growth problems and organ damage from iron overload in children with TDT. Currently approved medications have limitations for use in very young ...

Please provide your email address to receive an email when new articles are posted on . Iron chelation therapy with deferasirox conferred a clinically meaningful EFS benefit among ...

The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to ravage the globe, with cases reaching over 173 million. To date, there is ...

The addition of amlodipine to chelation therapy effectively reduced cardiac iron in patients with thalassemia major, according to a subgroup analysis of a randomized trial. Up to 50% of patients with ...

Beta thalassemia is a treatable blood disorder that’s inherited, or passed down through your genes. With beta thalassemia, your body doesn’t make enough hemoglobin, which is an important protein used ...